// company-profile

Outlook Therapeutics, Inc.

OTLK
ExchangeNasdaqSectorBiological Products, (No Diagnostic Substances)Inc.DEFilings54Insiders16
// api This Outlook Therapeutics, Inc. insider-trading data is served live by the Form4API insider trading API. Get the same data via API.

// activity-summary

Recent insider activity is bullish. Over the last 30 days, 9 insiders purchased shares (net $5.3M). Buying was led by Sukhtian Ghiath M..

// 90-day insight

Over the last 90 days, Outlook Therapeutics, Inc. insiders bought $5.3M across 9 transactions with no open-market sales.

  • Most active insider: Sukhtian Ghiath M. with 7 transactions totaling $5.0M.
  • Largest single purchase: $5.0M by Sukhtian Ghiath M. on May 28, 2026.

Activity skews bullish — buys outpace sales.

Institutional Ownership

Top 13F-HR holders of Outlook Therapeutics, Inc. as of 2026-03-31

↓ decreasing
Total reported AUM
$2.2M
QoQ change
-84.9%
Reporting period
2026-03-31
#1
ARMISTICE CAPITAL, LLC
CIK 1601086
$857,774
4.2M shares
#2
VANGUARD CAPITAL MANAGEMENT LLC
CIK 2100119
$405,235
2.0M shares
#3
GILPIN WEALTH MANAGEMENT, LLC
CIK 2058144
$123,514
600K shares

Data source: SEC Form 13F-HR filings. Joined with insider activity above — see who's loading up institutionally while insiders are trading. Full 13F-HR API →

Insider Transactions

Sourced from SEC EDGAR Form 4 filings. Updated hourly.

DateInsiderCompanyTypeSharesPriceValue
Jun 2, 2026Haddadin Yezan MuntherOTLK
Purchase
29,000$0.83$24K
May 28, 2026Sukhtian Ghiath M.OTLK
Purchase
8,571,428
May 28, 2026Sukhtian Ghiath M.OTLK
Purchase
8,539,709$0.59$5.00M
May 28, 2026Sukhtian Ghiath M.OTLK
H
3,458,571
May 28, 2026Sukhtian Ghiath M.OTLK
Purchase
3,458,571

45 more transactions hidden

Free account · No credit card required

Building something? Get API access →

Popular companies on Form4API

Browse insider trading activity for other actively-filed companies.